Eculizumab

BOSTON — Eculizumab significantly reduced disease severity and improved quality of life at 26 weeks in adolescents with refractory generalized myasthenia gravis, according to a presenter at the American Academy of Neurology annual meeting.

Pegcetacoplan led to greater improvements in hemoglobin compared with eculizumab among patients with paroxysmal nocturnal hemoglobinuria, according to results of the phase 3 PEGASUS study published in The New England Journal of Medicine.

The FDA granted priority review to pegcetacoplan for treatment of paroxysmal nocturnal hemoglobinuria, according to the agent’s manufacturer.